BMY 📈 Bristol-Myers Squibb - Overview

Bristol-Myers Squibb Company is a global biopharmaceutical entity that engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of a wide range of pharmaceutical products. The company's product portfolio is diverse, catering to various therapeutic areas including hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. This extensive range of products underscores the company's commitment to addressing complex medical conditions that affect a significant portion of the global population.

Among its key offerings, Bristol-Myers Squibb has Eliquis, which is used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment of deep vein thrombosis and pulmonary embolism. The company also markets Opdivo, a medication with multiple anti-cancer indications, including but not limited to bladder, blood, colorectal, head and neck, renal cell, hepatocellular, lung, melanoma, mesothelioma, stomach, and esophageal cancers. Additionally, Pomalyst/Imnovid is provided for the treatment of multiple myeloma, while Orencia is used for active rheumatoid arthritis and psoriatic arthritis, and Sprycel is utilized for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

The company's product lineup further includes Yervoy for the treatment of unresectable or metastatic melanoma, Empliciti for multiple myeloma, Abecma for relapsed or refractory multiple myeloma, Reblozyl for the treatment of anemia, Opdualag for unresectable or metastatic melanoma, and Zeposia for relapsing forms of multiple sclerosis. Moreover, Bristol-Myers Squibb offers Breyanzi for relapsed or refractory large B-cell lymphoma, Onureg for acute myeloid leukemia, Inrebic for myelofibrosis, Camzyos for symptomatic obstructive hypertrophic cardiomyopathy, Sotyktu for moderate-to-severe plaque psoriasis, Augtyro for locally advanced or metastatic ROS1-positive non-small cell lung cancer, Revlimid for multiple myeloma, and Abraxane for breast cancer, non-small cell lung cancer, and pancreatic cancer.

Bristol-Myers Squibb's distribution network is comprehensive, selling its products to a wide array of customers including wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. With a history dating back to 1887, the company, formerly known as Bristol-Myers Company, has evolved significantly over the years, establishing itself as a major player in the pharmaceutical industry. Headquartered in Princeton, New Jersey, Bristol-Myers Squibb continues to innovate and expand its product offerings, aiming to improve the lives of patients worldwide. For more information, the company can be visited at https://www.bms.com, with its stock traded under the ISIN US1101221083 as a common stock, classified under the GICS Sub Industry of Pharmaceuticals.